Cancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized with an inactivated (CoronaVac) or homologous (BNT162b2) SARS-CoV-2 vaccine. The primary outcome was the proportion of patients with anti-SARS-CoV-2 neutralizing antibody (NAb) seropositivity at 8-12 weeks post-booster. The secondary end points included IgG antibody (TAb) seropositivity and specific T-cell responses. A total of 109 patients were included. Eighty-four (77%) had heterologous vaccine schedules (two doses of CoronaVac followed by the BNT162b2 booster) and twenty-five had (23%) homologous vaccine schedules (three doses of BNT162b2). IgG antibody positivity for the homologous and heterologous regimen were 100% and 96% ( = 0.338), whereas NAb positivity reached 100% and 92% ( = 0.13), respectively. Absolute NAb positivity and Tab levels were associated with the homologous schedule (with a beta coefficient of 0.26 with = 0.027 and a geometric mean ratio 1.41 with = 0.044, respectively). Both the homologous and heterologous vaccine regimens elicited a strong humoral and cellular response after the BNT162b2 booster. The homologous regimen was associated with higher NAb positivity and Tab levels after adjusting for relevant covariates.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384024 | PMC |
| http://dx.doi.org/10.3390/vaccines11071193 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study.
Cancer Commun (Lond)
January 2025
Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Centre, Shanghai, P. R. China.
Background: Hormone receptor-positive (HR+)/humaal growth factor receptor 2-negative (HER2-) breast cancer, the most common breast cancer type, has variable prognosis and high recurrence risk. Neoadjuvant therapy is recommended for median-high risk HR+/HER2- patients. This phase II, single-arm, prospective study aimed to explore appropriate neoadjuvant treatment strategies for HR+/HER2- breast cancer patients.
View Article and Find Full Text PDFMolecular epidemiology of carbapenem-resistant group in Taiwan.
mSphere
December 2024
Department of Microbiology and Immunology, School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
particularly the group, is a major cause of nosocomial infections, and carbapenem-resistant spp. are important human pathogens. We collected 492 spp.
View Article and Find Full Text PDFImpact of anti-PD1 immunotherapy and circulating tumor cells on progression-free survival in surgical pancreatic adenocarcinoma: a retrospective cohort study.
Expert Rev Clin Immunol
January 2025
Department of Hepatobiliary, The Second Affiliated Hospital of Army Medical University, Chongqing, China.
Introduction: The clinical benefits of combining immunotherapy with chemotherapy and surgical resection in pancreatic adenocarcinoma remain unclear. The expression and clinical significance of HIF1A in circulating tumor cells (CTCs) in pancreatic adenocarcinoma remains limited.
Methods: This retrospective cohort study compared survival outcomes in pancreatic adenocarcinoma patients treated with two regimens: surgery+chemotherapy (nab-paclitaxel plus gemcitabine)+anti-PD1 (Tislelizumab) (S+AG+anti-PD1) ( = 37), and surgery+chemotherapy (S+AG) ( = 5).
Zika virus infections and associated risk factors among pregnant women in Gombe, Nigeria.
Virol Sin
December 2024
Department of Medical Laboratory Science, University of Maiduguri, College of Medical Sciences, P.M.B. 1069, Maiduguri, Nigeria. Electronic address:
Article Synopsis
- In-utero exposure to Zika virus (ZIKV) can result in severe outcomes like miscarriage and congenital Zika syndrome, prompting a study on the infection rates among pregnant women from February to April 2022.
- Researchers tested 200 pregnant women for ZIKV antibodies and found that 16.5% had ZIKV IgM, 10% had IgG, and 23% had neutralizing antibodies, indicating various stages of infection and immunity.
- The study also revealed that recent ZIKV infections were more common in sexually active women aged 20-29, with higher infection risks in first trimester and grand-multiparous women, although no significant link was found between ZIKV and specific pregnancy trimest
Theta Rhythm-Based Attention Switch Training Effectively Modified Negative Attentional Bias.
CNS Neurosci Ther
December 2024
Institute of Brain and Psychological Sciences, Sichuan Normal University, Chengdu, China.
Background: Attentional bias modification training (ABMT) is commonly employed to regulate negative attentional bias (NAB) and, in turn, to prevent or alleviate depressive symptoms. Recent advancements in attention switch theory have facilitated the development of a novel training paradigm that may enhance the efficacy of such interventions.
Methods: A total of fifty-seven college students were assigned to two groups: one exhibiting NAB and the other without.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!